Cellex Cell Professionals, a Germany-based Contract Development and Manufacturing Organisation (CDMO), on Monday reported continued success in its partnership with Gift of Life Biologics, a supplier of cellular starting materials in the US.
Established in 2022, the partnership focuses on supplying tailored cellular starting materials for cell and gene therapy (CGT) manufacturing. It supports research, clinical and commercial production by meeting complex donor specifications.
Gift of Life Biologics provides customised cellular materials from its FDA HCT/P registered and EMA GMP certified facility in the United States. These materials serve as the foundation for Cellex Cell Professionals' CDMO operations in Germany.
Cellex Cell Professionals, with over a decade of CGT experience, leverages this partnership to meet strict regulatory and therapeutic demands. While Cellex operates its own collection centre and donor network, the collaboration with Gift of Life Biologics enables the company to fulfil highly specialised donor requirements for its clients.
The two companies plan to expand their collaboration to support future innovation and global CGT advancements.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA